Skip to content

Study · Observational study · n = 8,278 · 2024

4 results

Comparative cardiovascular and renal outcomes of Liraglutide versus Dulaglutide in Asian type 2 diabetes patients.

Dai JW, Lin Y, Li XW, Tseng CJ, Tsai ML, Yang NI, Hung MJ, Chen TH

Scientific reports11 Nov 2024Cited by 2 (Europe PMC)

PMID39528690 (opens in a new tab)PMCIDPMC11555252 (opens in a new tab)DOI10.1038/s41598-024-79255-9 (opens in a new tab)PepBankPUB-39528690
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, the risk of composite cardiovascular outcomes did not significantly differ between liraglutide and dulaglutide.

    In plain wordsIn adults with type 2 diabetes, liraglutide and dulaglutide had similar risk of heart and stroke events.

    Peptide
    Liraglutide
    Outcome
    No significant changeComposite cardiovascular outcome
    Study

    n = 8,278

    Comparator
    Dulaglutide
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Incidence
    18.4 events per 1000 person-years
    liraglutide
    Incidence
    18.7 events per 1000 person-years
    dulaglutide
    Hazard ratio
    0.99
    liraglutide vs dulaglutide

    Source sentences

    Summary
    The risk of cardiovascular outcomes did not significantly differ between groups (hazard ratio [HR] 0.99, 95% confidence interval [CI] 0.85-1.15).
    2 context sentences
    Summary · context
    In the adjusted cohort by applying inverse probability of treatment weighting, the incidence of composite cardiovascular outcomes was 18.4 and 18.7 events per 1000 person-years in the liraglutide and dulaglutide groups, respectively.
    Summary · context
    In this new-user design, comparative and retrospective cohort study, patients with type 2 diabetes mellitus with prescription for GLP-1RAs from January 1, 2016 to December 31, 2022 (n = 8,278) were included.
  2. 02HumanObservational studyEfficacy outcome

    In patients with type 2 diabetes, dulaglutide and liraglutide were linked to similar risks of composite cardiovascular outcomes.

    In plain wordsIn patients with type 2 diabetes, dulaglutide and liraglutide were linked to similar cardiovascular outcome risks.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeComposite cardiovascular outcomes
    Study

    n = 8,278

    Comparator
    Liraglutide
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Incidence of composite cardiovascular outcomes
    18.4 events per 1000 person-years
    Liraglutide, IPTW-adjusted
    Incidence of composite cardiovascular outcomes
    18.7 events per 1000 person-years
    Dulaglutide, IPTW-adjusted
    Hazard ratio
    0.99 hazard ratio
    Dulaglutide versus liraglutide, IPTW-adjusted
    95% CI
    0.85 to 1.15 hazard ratio
    95% CI of the hazard ratio

    Source sentences

    Summary
    The risk of cardiovascular outcomes did not significantly differ between groups (hazard ratio [HR] 0.99, 95% confidence interval [CI] 0.85-1.15).
    3 context sentences
    Summary · context
    In the adjusted cohort by applying inverse probability of treatment weighting, the incidence of composite cardiovascular outcomes was 18.4 and 18.7 events per 1000 person-years in the liraglutide and dulaglutide groups, respectively.
    Summary · context
    In this new-user design, comparative and retrospective cohort study, patients with type 2 diabetes mellitus with prescription for GLP-1RAs from January 1, 2016 to December 31, 2022 (n = 8,278) were included.
    Summary · context
    A total of 3,210 subjects receiving liraglutide and 5,068 subjects receiving dulaglutide were identified.
  3. 03HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, the risk of composite renal outcomes was comparable between liraglutide and dulaglutide.

    In plain wordsIn adults with type 2 diabetes, liraglutide and dulaglutide had similar risk of kidney outcomes.

    Peptide
    Liraglutide
    Outcome
    No significant changeComposite renal outcome
    Study

    n = 8,278

    Comparator
    Dulaglutide
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    Subdistribution hazard ratio
    1.07
    liraglutide vs dulaglutide

    Source sentences

    Summary
    Moreover, the risk of composite renal outcomes was also comparable between groups (subdistribution HR 1.07, 95% CI 0.995-1.16).
    1 context sentence
    Summary · context
    In this new-user design, comparative and retrospective cohort study, patients with type 2 diabetes mellitus with prescription for GLP-1RAs from January 1, 2016 to December 31, 2022 (n = 8,278) were included.
  4. 04HumanObservational studyEfficacy outcome

    In patients with type 2 diabetes, dulaglutide and liraglutide were linked to comparable risks of composite renal outcomes.

    In plain wordsIn patients with type 2 diabetes, dulaglutide and liraglutide were linked to similar kidney outcome risks.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeComposite renal outcomes
    Study

    n = 8,278

    Comparator
    Liraglutide
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    Subdistribution hazard ratio
    1.07 subdistribution hazard ratio
    Dulaglutide versus liraglutide
    95% CI
    0.995 to 1.16 subdistribution hazard ratio
    95% CI

    Source sentences

    Summary
    Moreover, the risk of composite renal outcomes was also comparable between groups (subdistribution HR 1.07, 95% CI 0.995-1.16).
    2 context sentences
    Summary · context
    In this new-user design, comparative and retrospective cohort study, patients with type 2 diabetes mellitus with prescription for GLP-1RAs from January 1, 2016 to December 31, 2022 (n = 8,278) were included.
    Summary · context
    A total of 3,210 subjects receiving liraglutide and 5,068 subjects receiving dulaglutide were identified.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 9Current

    28 Oct 2026, 02:03 UTC

    The same notice was added 6 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.

    Study results updated

  2. Version 3

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 2

    12 Oct 2026, 11:11 UTC

    Study results updated

  4. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.